Pfizer and BioNTech say a three-shot course of their COVID-19 vaccine was able to neutralize the new omicron variant in a laboratory test, and that they could deliver an omicron-based vaccine in March 2022 if needed. But the companies also note their data is "preliminary."
Post a Comment